Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.
Identifieur interne : 001866 ( Ncbi/Merge ); précédent : 001865; suivant : 001867Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.
Auteurs : Joong-Seok Kim [Corée du Sud] ; Phil-Hyu Lee ; Kwang-Soo Lee ; Jeong-Wook Park ; Yeong-In Kim ; Yong-An Chung ; Sung-Hoon Kim ; Seung-Hyun Kim ; Juhan Kim ; Yun-Young Choi ; Hee-Tae KimSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- 3-Iodobenzylguanidine (diagnostic use), 3-Iodobenzylguanidine (pharmacokinetics), Aged, Aged, 80 and over, Case-Control Studies, Cerebrovascular Disorders (drug therapy), Cerebrovascular Disorders (metabolism), Cerebrovascular Disorders (radionuclide imaging), Female, Heart (physiopathology), Heart (radionuclide imaging), Humans, Male, Middle Aged, Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (metabolism), Parkinsonian Disorders (radionuclide imaging), Radionuclide Imaging (methods), Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (pharmacokinetics).
- MESH :
- chemical , diagnostic use : 3-Iodobenzylguanidine, Radiopharmaceuticals.
- chemical , pharmacokinetics : 3-Iodobenzylguanidine, Radiopharmaceuticals.
- drug therapy : Cerebrovascular Disorders, Parkinsonian Disorders.
- metabolism : Cerebrovascular Disorders, Parkinsonian Disorders.
- methods : Radionuclide Imaging.
- physiopathology : Heart.
- radionuclide imaging : Cerebrovascular Disorders, Heart, Parkinsonian Disorders.
- Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Male, Middle Aged.
Abstract
The purpose of our study was to prospectively evaluate cardiac [(123)I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age-matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 +/- 0.41 vs. 1.27 +/- 0.13; P < 0.001). MIBG uptake did not differ between VP and controls (2.46 +/- 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice.
DOI: 10.1002/mds.21112
PubMed: 16991157
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A73
- to stream PubMed, to step Curation: 002A73
- to stream PubMed, to step Checkpoint: 002E35
Links to Exploration step
pubmed:16991157Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.</title><author><name sortKey="Kim, Joong Seok" sort="Kim, Joong Seok" uniqKey="Kim J" first="Joong-Seok" last="Kim">Joong-Seok Kim</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Neurology, The Catholic University of Korea, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Lee, Phil Hyu" sort="Lee, Phil Hyu" uniqKey="Lee P" first="Phil-Hyu" last="Lee">Phil-Hyu Lee</name></author><author><name sortKey="Lee, Kwang Soo" sort="Lee, Kwang Soo" uniqKey="Lee K" first="Kwang-Soo" last="Lee">Kwang-Soo Lee</name></author><author><name sortKey="Park, Jeong Wook" sort="Park, Jeong Wook" uniqKey="Park J" first="Jeong-Wook" last="Park">Jeong-Wook Park</name></author><author><name sortKey="Kim, Yeong In" sort="Kim, Yeong In" uniqKey="Kim Y" first="Yeong-In" last="Kim">Yeong-In Kim</name></author><author><name sortKey="Chung, Yong An" sort="Chung, Yong An" uniqKey="Chung Y" first="Yong-An" last="Chung">Yong-An Chung</name></author><author><name sortKey="Kim, Sung Hoon" sort="Kim, Sung Hoon" uniqKey="Kim S" first="Sung-Hoon" last="Kim">Sung-Hoon Kim</name></author><author><name sortKey="Kim, Seung Hyun" sort="Kim, Seung Hyun" uniqKey="Kim S" first="Seung-Hyun" last="Kim">Seung-Hyun Kim</name></author><author><name sortKey="Kim, Juhan" sort="Kim, Juhan" uniqKey="Kim J" first="Juhan" last="Kim">Juhan Kim</name></author><author><name sortKey="Choi, Yun Young" sort="Choi, Yun Young" uniqKey="Choi Y" first="Yun-Young" last="Choi">Yun-Young Choi</name></author><author><name sortKey="Kim, Hee Tae" sort="Kim, Hee Tae" uniqKey="Kim H" first="Hee-Tae" last="Kim">Hee-Tae Kim</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.21112</idno><idno type="RBID">pubmed:16991157</idno><idno type="pmid">16991157</idno><idno type="wicri:Area/PubMed/Corpus">002A73</idno><idno type="wicri:Area/PubMed/Curation">002A73</idno><idno type="wicri:Area/PubMed/Checkpoint">002E35</idno><idno type="wicri:Area/Ncbi/Merge">001866</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.</title><author><name sortKey="Kim, Joong Seok" sort="Kim, Joong Seok" uniqKey="Kim J" first="Joong-Seok" last="Kim">Joong-Seok Kim</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Neurology, The Catholic University of Korea, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Lee, Phil Hyu" sort="Lee, Phil Hyu" uniqKey="Lee P" first="Phil-Hyu" last="Lee">Phil-Hyu Lee</name></author><author><name sortKey="Lee, Kwang Soo" sort="Lee, Kwang Soo" uniqKey="Lee K" first="Kwang-Soo" last="Lee">Kwang-Soo Lee</name></author><author><name sortKey="Park, Jeong Wook" sort="Park, Jeong Wook" uniqKey="Park J" first="Jeong-Wook" last="Park">Jeong-Wook Park</name></author><author><name sortKey="Kim, Yeong In" sort="Kim, Yeong In" uniqKey="Kim Y" first="Yeong-In" last="Kim">Yeong-In Kim</name></author><author><name sortKey="Chung, Yong An" sort="Chung, Yong An" uniqKey="Chung Y" first="Yong-An" last="Chung">Yong-An Chung</name></author><author><name sortKey="Kim, Sung Hoon" sort="Kim, Sung Hoon" uniqKey="Kim S" first="Sung-Hoon" last="Kim">Sung-Hoon Kim</name></author><author><name sortKey="Kim, Seung Hyun" sort="Kim, Seung Hyun" uniqKey="Kim S" first="Seung-Hyun" last="Kim">Seung-Hyun Kim</name></author><author><name sortKey="Kim, Juhan" sort="Kim, Juhan" uniqKey="Kim J" first="Juhan" last="Kim">Juhan Kim</name></author><author><name sortKey="Choi, Yun Young" sort="Choi, Yun Young" uniqKey="Choi Y" first="Yun-Young" last="Choi">Yun-Young Choi</name></author><author><name sortKey="Kim, Hee Tae" sort="Kim, Hee Tae" uniqKey="Kim H" first="Hee-Tae" last="Kim">Hee-Tae Kim</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Iodobenzylguanidine (diagnostic use)</term><term>3-Iodobenzylguanidine (pharmacokinetics)</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Cerebrovascular Disorders (drug therapy)</term><term>Cerebrovascular Disorders (metabolism)</term><term>Cerebrovascular Disorders (radionuclide imaging)</term><term>Female</term><term>Heart (physiopathology)</term><term>Heart (radionuclide imaging)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (metabolism)</term><term>Parkinsonian Disorders (radionuclide imaging)</term><term>Radionuclide Imaging (methods)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Radiopharmaceuticals (pharmacokinetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cerebrovascular Disorders</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Cerebrovascular Disorders</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radionuclide Imaging</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Heart</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Cerebrovascular Disorders</term><term>Heart</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of our study was to prospectively evaluate cardiac [(123)I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age-matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 +/- 0.41 vs. 1.27 +/- 0.13; P < 0.001). MIBG uptake did not differ between VP and controls (2.46 +/- 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16991157</PMID><DateCreated><Year>2006</Year><Month>12</Month><Day>05</Day></DateCreated><DateCompleted><Year>2007</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.</ArticleTitle><Pagination><MedlinePgn>1990-4</MedlinePgn></Pagination><Abstract><AbstractText>The purpose of our study was to prospectively evaluate cardiac [(123)I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during the course of their CVD were enrolled in the study; 16 age-matched subjects, and 30 patients with Parkinson's disease (PD) were also evaluated with cardiac MIBG uptake. MIBG uptake was assessed using the ratio of the heart to the upper mediastinum (H/M) according to planar scintigraphic data. The mean H/M ratio was significantly higher in patients with VP than in those with PD (2.28 +/- 0.41 vs. 1.27 +/- 0.13; P < 0.001). MIBG uptake did not differ between VP and controls (2.46 +/- 0.33; P > 0.05). Our findings suggest that myocardial postganglionic sympathetic dysfunction found in PD is absent in most patients with VP. MIBG single photon emission computed tomography imaging may be useful to help distinguish between PD and VP patients in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joong-Seok</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Phil-Hyu</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kwang-Soo</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jeong-Wook</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeong-In</ForeName><Initials>YI</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Yong-An</ForeName><Initials>YA</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sung-Hoon</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seung-Hyun</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Juhan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Yun-Young</ForeName><Initials>YY</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hee-Tae</ForeName><Initials>HT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Studies</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>35MRW7B4AD</RegistryNumber><NameOfSubstance UI="D019797">3-Iodobenzylguanidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019797">3-Iodobenzylguanidine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002561">Cerebrovascular Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011877">Radionuclide Imaging</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21112</ArticleId><ArticleId IdType="pubmed">16991157</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li></country><settlement><li>Séoul</li></settlement></list><tree><noCountry><name sortKey="Choi, Yun Young" sort="Choi, Yun Young" uniqKey="Choi Y" first="Yun-Young" last="Choi">Yun-Young Choi</name><name sortKey="Chung, Yong An" sort="Chung, Yong An" uniqKey="Chung Y" first="Yong-An" last="Chung">Yong-An Chung</name><name sortKey="Kim, Hee Tae" sort="Kim, Hee Tae" uniqKey="Kim H" first="Hee-Tae" last="Kim">Hee-Tae Kim</name><name sortKey="Kim, Juhan" sort="Kim, Juhan" uniqKey="Kim J" first="Juhan" last="Kim">Juhan Kim</name><name sortKey="Kim, Seung Hyun" sort="Kim, Seung Hyun" uniqKey="Kim S" first="Seung-Hyun" last="Kim">Seung-Hyun Kim</name><name sortKey="Kim, Sung Hoon" sort="Kim, Sung Hoon" uniqKey="Kim S" first="Sung-Hoon" last="Kim">Sung-Hoon Kim</name><name sortKey="Kim, Yeong In" sort="Kim, Yeong In" uniqKey="Kim Y" first="Yeong-In" last="Kim">Yeong-In Kim</name><name sortKey="Lee, Kwang Soo" sort="Lee, Kwang Soo" uniqKey="Lee K" first="Kwang-Soo" last="Lee">Kwang-Soo Lee</name><name sortKey="Lee, Phil Hyu" sort="Lee, Phil Hyu" uniqKey="Lee P" first="Phil-Hyu" last="Lee">Phil-Hyu Lee</name><name sortKey="Park, Jeong Wook" sort="Park, Jeong Wook" uniqKey="Park J" first="Jeong-Wook" last="Park">Jeong-Wook Park</name></noCountry><country name="Corée du Sud"><noRegion><name sortKey="Kim, Joong Seok" sort="Kim, Joong Seok" uniqKey="Kim J" first="Joong-Seok" last="Kim">Joong-Seok Kim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001866 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001866 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:16991157
|texte= Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16991157" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |